Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q34777664)
Watch
English
Non-peptide arginine-vasopressin antagonists: the vaptans
scientific article
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PubMed ID
18468546
retrieved
4 August 2017
review article
1 reference
stated in
Europe PubMed Central
title
Non-peptide arginine-vasopressin antagonists: the vaptans
(English)
1 reference
stated in
Europe PubMed Central
PubMed ID
18468546
retrieved
4 August 2017
main subject
AVP
0 references
author
Gilbert Vassart
series ordinal
3
object named as
Gilbert Vassart
1 reference
stated in
Europe PubMed Central
PubMed ID
18468546
retrieved
4 August 2017
author name string
Guy Decaux
series ordinal
1
1 reference
stated in
Europe PubMed Central
PubMed ID
18468546
retrieved
4 August 2017
Alain Soupart
series ordinal
2
1 reference
stated in
Europe PubMed Central
PubMed ID
18468546
retrieved
4 August 2017
language of work or name
English
0 references
publication date
1 May 2008
1 reference
stated in
Europe PubMed Central
PubMed ID
18468546
retrieved
4 August 2017
published in
The Lancet
1 reference
stated in
Europe PubMed Central
PubMed ID
18468546
retrieved
4 August 2017
volume
371
1 reference
stated in
Europe PubMed Central
PubMed ID
18468546
retrieved
4 August 2017
page(s)
1624-1632
1 reference
stated in
Europe PubMed Central
PubMed ID
18468546
retrieved
4 August 2017
issue
9624
1 reference
stated in
Europe PubMed Central
PubMed ID
18468546
retrieved
4 August 2017
cites work
Antidiuretic action of vasopressin: quantitative aspects and interaction between V1a and V2 receptor-mediated effects
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The central vasopressinergic system: examining the opportunities for psychiatric drug development
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Pancreatic vasopressin V1breceptors: characterization in In-R1-G9 cells and localization in human pancreas
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Identification of the binding sites of the SR49059 nonpeptide antagonist into the V1a vasopressin receptor using sulfydryl-reactive ligands and cysteine mutants as chemical sensors
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The basic and clinical pharmacology of nonpeptide vasopressin receptor antagonists
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Vasopressin antagonists
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Vasopressin V2 receptor antagonists
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Vaptans and the treatment of water-retaining disorders
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Vasopressin receptor antagonists
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Evaluation and management of hyponatremia: an emerging role for vasopressin receptor antagonists
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Vasopressin antagonists: role in the management of hyponatremia
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Molecular biology of hereditary diabetes insipidus.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Nephrogenic syndrome of inappropriate antidiuresis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Nephrogenic syndrome of inappropriate antidiuresis in adults: high phenotypic variability in men and women from a large pedigree.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Mapping the binding site of six nonpeptide antagonists to the human V2-renal vasopressin receptor
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin V1a receptors
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Effect of SR 49059, a V1a vasopressin receptor antagonist, in Raynaud's phenomenon
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The effect of relcovaptan (SR 49059), an orally active vasopressin V1a receptor antagonist, on uterine contractions in preterm labor
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
OPC-21268, an Orally Effective, Nonpeptide Vasopressin V1 Receptor Antagonist
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
In vivo and in vitro effects of AVP and V1a receptor antagonist on Cushing's syndrome due to ACTH-independent bilateral macronodular adrenocortical hyperplasia.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Pharmacologic management of Cushing syndrome : new targets for therapy.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
New approach to disturbances in the plasma sodium concentration
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Conivaptan: a selective vasopressin antagonist for the treatment of heart failure
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Neurohormonal inhibition in heart failure: insights from recent clinical trials
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Nonpeptide arginine vasopressin antagonists for both V1A and V2 receptors: synthesis and pharmacological properties of 2-phenyl-4'-[(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]benzanil ide derivatives
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Potent aquaretic agent. A novel nonpeptide selective vasopressin 2 antagonist (OPC-31260) in men.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Acute aquaresis by the nonpeptide arginine vasopressin (AVP) antagonist OPC-31260 improves hyponatremia in patients with syndrome of inappropriate secretion of antidiuretic hormone (SIADH)
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Vasopressin antagonists in polycystic kidney disease
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Long-term treatment of patients with inappropriate secretion of antidiuretic hormone by the vasopressin receptor antagonist conivaptan, urea, or furosemide
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Sodium
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Hyponatremia
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Hyponatremia in patients with heart failure
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Incidence and factors predictive of acute renal failure in patients with advanced liver cirrhosis.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Neurological impact of vasopressin dysregulation and hyponatremia
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Admission hyponatremia in the elderly: factors influencing prognosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: long-term effects.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Treatment of symptomatic hyponatremia
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Management of severe hyponatremia: rapid or slow correction?
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Pharmacologic chaperones as a potential treatment for X-linked nephrogenic diabetes insipidus.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Intravenous administration of conivaptan hydrochloride improves cardiac hemodynamics in rats with myocardial infarction-induced congestive heart failure
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Effect of SR121463, a selective non-peptide vasopressin V2 receptor antagonist, in a rabbit model of ocular hypertension
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The effects of several vasopressin receptor antagonists on normal intraocular pressure and the intraocular distribution of vasopressin receptor subtypes
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The effects of V2 antagonist (OPC-31260) on endolymphatic hydrops
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Vasopressin receptor antagonist OPC-31260 prevents cerebral oedema after subarachnoid haemorrhage.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Participation of vasopressin in the development of cerebral vasospasm in a rat model of subarachnoid haemorrhage.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Effects of nonpeptide V(1) vasopressin receptor antagonist SR-49059 on infarction volume and recovery of function in a focal embolic stroke model
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Oxytocin- and vasopressin-induced growth of human small-cell lung cancer is mediated by the mitogen-activated protein kinase pathway.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Identifiers
DOI
10.1016/S0140-6736(08)60695-9
1 reference
stated in
Europe PubMed Central
PubMed ID
18468546
retrieved
4 August 2017
PubMed ID
18468546
1 reference
stated in
Europe PubMed Central
PubMed ID
18468546
retrieved
4 August 2017
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit